Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/4/2025

Janusmed sex and gender

Janusmed sex and gender – Esomeprazole

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Esomeprazole testing environment

Esomeprazole

Class : A

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - NEXIUM (esomeprazole) [updated 2001-02-20].
  2. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40:411-26.
  3. Helgadóttir H, Metz DC, Yang YX, Rhim AD, Björnsson ES. The effects of long-term therapy with proton pump inhibitors on meal stimulated gastrin. Dig Liver Dis. 2014;46:125-30.
  4. Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. Ann Allergy Asthma Immunol. 2013;111:452-7.
  5. Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2014;170:342-51.
  6. NEXIUM (esomeprazole). Summary of Product Characteristics. European Medicines Agency (EMA); 2014.
  7. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  8. Hall J, Dodd S, Durkin M, Sloan S. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care. 2002;11:14-8.
  9. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222-39.
  10. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. Aliment Pharmacol Ther. 2009;29:959-66.
  11. Linton A, Bacon T, Peterson M. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary. J Manag Care Pharm. 2009;15:42-54.
  12. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.]